CUBEBIO Co., Ltd. Completes the Export Contract for Cancer Self-Diagnostic Devices Worth 3 Trillion Won (USD 2.5 Billion) with Russia

CUBEBIO Co., Ltd. Completes the Export Contract for Cancer Self-Diagnostic Devices Worth 3 Trillion Won (USD 2.5 Billion) with Russia/Photo=CUBUBIO Co., LTD

CUBEBIO, an in vitro diagnostic company in Seoul, South Korea, signed the exclusive contract with Russia’s 《Standart-Biotest》 LLC at the Hertsen Moscow Oncology Research Institute in Moscow, Russia, on the 27th of September to export cancer self-diagnostic devices developed by CUBEBIO to Russia and the Commonwealth of Independent States, an organization made up of ten post-Soviet republics.
《Standart-Biotest》 LLC Representatives (left), CUBEBIO Co., Ltd. Representatives (right)


This is followed by the completion of MoU signed in Russia last July, which has led to the signing of this contract, as 《Standart-Biotest》 LLC cooperates with Russia’s National Medical Research Radiological Center, a member of the Union for International Cancer Control (UICC). Established in 1898, Russia’s National Medical Research Radiological Center is composed of the Hertsen Moscow Oncology Research Institute, the oldest cancer clinic in Europe, and two other research centers with 905 beds and over 3,300 medical professionals.
CUBEBIO’s cancer self-diagnostic device is a device that allows anyone to diagnose cancers conveniently without the help of medical personnel at home, health clinics, and hospitals by using urine as a specimen. It consists of standard units that can differentiate between the presence and non-presence of cancer. Units for diagnosing common cancer types and those for diagnosing additional types of cancer are also included for use when test results are positive. Therefore, the cancer self-diagnostic device is a multi-tracking system that cannot only find cancer at an early stage, but also check exact types of cancer. Since the device is the in vitro diagnostic device with urine as the specimen collected from the human body, safety is highly assured with no side effects on the human body. Compared to new drugs or other medical devices, permission can be obtained relatively easily and simply.
《Standart-Biotest》 LLC, which has completed the contract with CUBEBIO, is supported by the Ministry of Health of the Russian Federation and the National Medical Research Radiological Center, the Federal State Budgetary Institution of the Ministry of Health of the Russian Federation. 《Standart-Biotest》 LLC is the corporation leading the advancement in the field of cancer diagnosis in the Russian market with the implementation of a national health strategy for cancer diagnosis and treatment. This business receives support from the Hertsen Moscow Oncology Research Institute, and CUBEBIO is to proceed with the delivery of cancer self-diagnostic devices with the Ministry of Health of the Russian Federation.
Currently, cancer death rates are increasing every year in Russia. According to the International Agency for Research on Cancer in affiliation with the World Health Organization, the number of new cancer cases in Russia reached 543,045. Cancer with the highest incidence rate in Russia is breast cancer, and lung cancer has the highest death rate. In 2017, the Ministry of Health of the Russian Federation enacted a national policy, which would allow Russian citizens to undergo regular checkups once every three years. Through this policy, 29.4% of Russia’s total population should have received mandatory medical examinations, and the number is expected to rise gradually.

“We are pleased that this contract will contribute to the implementation of the national health policy related to cancer diagnosis in Russia,” said CUBEBIO. CUBEBIO continued to state that “negotiations with China, Southeast Asia, the Middle East, and South Africa are underway in a rapid manner.” Accordingly, it is reported that additional medical device manufacturers are being searched in multiple ways for the stable mass production and supply of cancer self-diagnostic devices.
After this contract, CUBEBIO is to complete the process of obtaining permission from the Russian FDA with 《Standart-Biotest》 LLC. And CUBEBIO is scheduled to export cancer self-diagnostic devices after confirming the procedure needed for the customization of the device for Russian citizens as well as the stable production and quantity for the supply of devices with cancer self-diagnostic device manufacturers.
With the aim of creating a global culture where anyone can easily self-diagnose cancers at home, CUBEBIO is expanding its efforts to increase the chance for recovery through early diagnosis of cancer by first targeting UICC’s 172 member countries, in order to fulfil the role as a Patron partner, which is the highest partnership level, with UICC.